Edition:
United States

Lennox International Inc (LII.N)

LII.N on New York Stock Exchange

206.66USD
21 May 2018
Change (% chg)

$2.80 (+1.37%)
Prev Close
$203.86
Open
$205.00
Day's High
$207.20
Day's Low
$204.32
Volume
60,007
Avg. Vol
95,915
52-wk High
$222.31
52-wk Low
$160.18

Select another date:

Tue, May 15 2018

BRIEF-Lennox International Increases Dividend 25 Percent

* SETS QUARTERLY CASH DIVIDEND OF $0.64PER SHARE Source text for Eikon: Further company coverage:

BRIEF-Lennox International Reports Q1 Adjusted Earnings Per Share $1.13 From Continuing Operations

* LENNOX INTERNATIONAL REPORTS RECORD FIRST-QUARTER REVENUE AND PROFIT

BRIEF-Lennox International Says CEO's 2017 Compensation Was $11.45 Mln

* LENNOX INTERNATIONAL INC SAYS CEO TODD M. BLUEDORN'S 2017 TOTAL COMPENSATION WAS $11.45 MILLION VERSUS $10 MILLION IN 2016 – SEC FILING‍​ Source: (https://bit.ly/2GUhs6F) Further company coverage:

BRIEF-Lennox International Q4 EPS $1.02 From Continuing Operations

* LENNOX INTERNATIONAL REPORTS RECORD FOURTH QUARTER MARGIN AND PROFIT TO CAP RECORD YEAR AND RAISES 2018 EPS GUIDANCE FOR U.S. TAX LEGISLATION

BRIEF-Ovid Therapeutics Announces TAK-935/OV935 Granted Orphan Drug Designation By U.S. FDA For Treatment Of Lennox-Gastaut Syndrome

* OVID THERAPEUTICS ANNOUNCES TAK-935/OV935 GRANTED ORPHAN DRUG DESIGNATION BY U.S. FDA FOR TREATMENT OF LENNOX-GASTAUT SYNDROME

BRIEF-Lennox International Sees Fy18 Revenue Up 3 To 7 Percent

* REAFFIRMS FY 2017 ADJUSTED EARNINGS PER SHARE VIEW $7.75 TO $8.05 FROM CONTINUING OPERATIONS

Select another date: